No headlines found.
Business Wire (Mon, 1-Dec 9:25 AM ET)
Business Wire (Mon, 10-Nov 10:00 AM ET)
Business Wire (Tue, 14-Oct 3:02 AM ET)
Business Wire (Mon, 15-Sep 6:24 PM ET)
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
Business Wire (Thu, 11-Sep 9:54 PM ET)
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Apimeds Pharmaceuticals US trades on the AMEX stock market under the symbol APUS.
As of December 9, 2025, APUS stock price was flat at $2.13 with 89,666 million shares trading.
APUS has a beta of 1.42, meaning it tends to be more sensitive to market movements. APUS has a correlation of 0.02 to the broad based SPY ETF.
APUS has a market cap of $26.79 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that APUS belongs to (by Net Assets): VXF.
APUS support price is $1.87 and resistance is $2.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APUS shares will trade within this expected range on the day.
